Clinical Trial Update: A Study to Evaluate the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of Idasanutlin Monotherapy in Participants With Hydroxyurea-Resistant/Intolerant Polycythemia Vera [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating idasanutlin monotherapy in hydroxyurea-resistant/intolerant polycythemia vera; study terminated with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Polycythemia Vera

Drugs mentioned

• Idasanutlin (Idasanutlin)

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Polycythemia Vera | Phase 2 | Status: TERMINATED | Results posted: 2021-05-27